BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20006005)

  • 1. Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.
    Tajiri T; Souzaki R; Kinoshita Y; Tanaka S; Koga Y; Suminoe A; Matsuzaki A; Hara T; Taguchi T
    J Pediatr Surg; 2009 Dec; 44(12):2253-7. PubMed ID: 20006005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan.
    Suita S; Tajiri T; Higashi M; Tanaka S; Kinoshita Y; Takahashi Y; Tatsuta K
    Eur J Pediatr Surg; 2007 Feb; 17(1):23-8. PubMed ID: 17407017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
    Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
    Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan.
    Kaneko Y; Kobayashi H; Watanabe N; Tomioka N; Nakagawara A
    Pediatr Blood Cancer; 2006 Mar; 46(3):285-91. PubMed ID: 16078225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in neuroblastoma. Usefulness of DNA analysis using flow cytometry on paraffin-embedded material].
    Massara FM; Tonello M; Forni M; Fruttero A; Lantermo R; Pugno F; Cordero di Montezemolo L; RuĂ  S
    Pediatr Med Chir; 1996; 18(2):141-8. PubMed ID: 8767575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors.
    Kerbl R; Urban CE; Ambros IM; Dornbusch HJ; Schwinger W; Lackner H; Ladenstein R; Strenger V; Gadner H; Ambros PF
    J Clin Oncol; 2003 Nov; 21(22):4228-34. PubMed ID: 14615452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.
    Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y
    Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems of mass screening for neuroblastoma: analysis of false-negative cases.
    Ishimoto K; Kiyokawa N; Fujita H; Yabuta K; Ohya T; Miyano T; Shinohara T; Sera Y
    J Pediatr Surg; 1990 Apr; 25(4):398-401. PubMed ID: 2329455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
    Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
    J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients.
    Hiyama E; Yamaoka H; Kamimatsuse A; Onitake Y; Hiyama K; Nishiyama M; Sueda T
    J Pediatr Surg; 2006 Dec; 41(12):2032-6. PubMed ID: 17161199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features and outcome of neuroblastoma detected before birth.
    Granata C; Fagnani AM; Gambini C; Boglino C; Bagnulo S; Cecchetto G; Federici S; Inserra A; Michelazzi A; Riccipetitoni G; Rizzo A; Tamaro P; Jasonni V; De Bernardi B
    J Pediatr Surg; 2000 Jan; 35(1):88-91. PubMed ID: 10646781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
    Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
    Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
    Suita S
    J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
    Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K
    J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
    Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
    Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
    Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
    J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
    Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
    J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.